Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Non-Hodgkin's Lymphoma

‘Relative’ chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma

Bone Marrow Transplantation volume 30, pages 885–891 (2002)Cite this article

Abstract

The purpose of the study was to assess the impact of number of salvage regimens needed to demonstrate chemotherapy sensitivity on relapse rates, survival, and toxicity following high-dose therapy and autologous bone marrow transplantation (ABMT) in relapsed or refractory non-Hodgkin's lymphoma. We retrospectively reviewed 136 patients with intermediate-grade lymphoma who underwent ABMT. All patients were treated with salvage therapy to maximum tumor reduction. Three quarters (102/136) of the patients received one salvage regimen, while 31 (23%) patients received two or more regimens. When compared to patients requiring ⩾ two regimens, patients requiring only one salvage regimen to demonstrate chemosensitivity were more likely to have a longer previous CR from initial therapy (CR ⩾12 months in 47% vs 26%; P = 0.04) and to have attained CR with salvage (54% vs 16%; P = 0.001). Both median relapse-free survival (RFS) and overall survival (OS) have not yet been reached in patients receiving one salvage regimen (median follow-up 50.6 months). This is superior to the median RFS of 9.1 months (P = 0.004) and OS of 11.1 months in patients requiring ⩾two regimens to demonstrate chemosensitivity (P = 0.002). Time to engraftment, toxic deaths and incidence of myelodysplasia were similar in the groups. The survival rate observed in patients requiring ⩾two salvage regimens, although inferior to that of patients receiving a single salvage regimen, are still generally superior to results in the literature for patients treated with chemotherapy alone without ABMT. We conclude that high-dose therapy with ABMT is appropriate for lymphoma patients even when disease reduction requires repeated numbers of salvage regimens.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Conde E, Sierra J, Iriondo A et al. Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the Spanish cooperative Group GEL/TAMO Bone Marrow Transplant 1994 14: 279 286

    CAS  PubMed  Google Scholar 

  2. Gulati S, Yahalom J, Acaba L et al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation J Clin Oncol 1992 10: 936 941

    Article  CAS  PubMed  Google Scholar 

  3. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma New Engl J Med 1989 316: 1493 1498

    Article  Google Scholar 

  4. Rapaport AP, Lifton R, Constine LS et al. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors Bone Marrow Transplant 1997 19: 883 890

    Article  Google Scholar 

  5. Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma J Clin Oncol 1993 11: 1846 1851

    Article  CAS  PubMed  Google Scholar 

  6. Prince HM, Imrie K, Crump M et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups Br J Haematol 1996 92: 880 889

    Article  CAS  PubMed  Google Scholar 

  7. Bezwoda WR, Bezwoda MA, Seymour L et al. NOPE for relapsed aggressive diffuse non-Hodgkin's lymphoma Leuk Lymphoma 1993 10: 329 333

    Article  CAS  PubMed  Google Scholar 

  8. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ . IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy Blood 1982 60: 693 697

    CAS  PubMed  Google Scholar 

  9. Cabanillas F, Hagemeister FB, McLaughlin P et al. Results of MIME salvage regimen for recurrent or refractory lymphoma J Clin Oncol 1987 5: 407 412

    Article  CAS  PubMed  Google Scholar 

  10. Girouard C, Dufresne J, Imrie K et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation Ann Oncol 1997 8: 675 680

    Article  CAS  PubMed  Google Scholar 

  11. Goss P, Shepherd F, Scott JG et al. DICE (dexamathasone, ifosphamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas Leuk Lymphoma 1995 18: 123 129

    Article  CAS  PubMed  Google Scholar 

  12. Rodriguez MA, Cabanillas FC, Velasquez W et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP J Clin Oncol 1995 13: 1734 1741

    Article  CAS  PubMed  Google Scholar 

  13. Sparano JA, Wiernick PH, Leaf A, Dutcher JP . Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy J Clin Oncol 1993 11: 1071 1079

    Article  CAS  PubMed  Google Scholar 

  14. Stamatoullas A, Fruchart C, Bastit D et al. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma Cancer 1996 77: 2302 2307

    Article  CAS  PubMed  Google Scholar 

  15. Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) Blood 1988 71: 117 122

    CAS  PubMed  Google Scholar 

  16. Wilson WH, Bryant G, Bates S et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma J Clin Oncol 1993 11: 1573 1582

    Article  CAS  PubMed  Google Scholar 

  17. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage Cancer 1982 49: 2112 2135

  18. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 1982 5: 649 655

    Article  CAS  PubMed  Google Scholar 

  19. Yee K, Tu J, MacKinnon J et al. Febrile neutropenia after hematopoietic stem cell mobilization with chemotherapy and G-CSF does not affect collection of adequate numbers of CD34+ cells Blood 1997 90: 214a

    Google Scholar 

  20. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma New Engl J Med 1993 329: 987 994

  21. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations Am Stat Assoc J 1958 53: 457 481

    Article  Google Scholar 

  22. Peto R, Peto J . Asymptomatically efficient rank invariant test procedures JR Stat Soc A 1972 135: 185 206

    Article  Google Scholar 

  23. Fleiss JL . Statistical Methods for Rates and Proportions 1973 Wiley: New York

    Google Scholar 

  24. Velasquez WS, McLaughlin P, Tucker S et al. ESHAP – an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study J Clin Oncol 1994 12: 1169 1176

    Article  CAS  PubMed  Google Scholar 

  25. McKelvey EM, Gottlieb JA, Wilson HE et al. Hydroxyldaunorubicin (adriamycin) combination chemotherapy in malignant lymphoma Cancer 1976 38: 1484 1493

    Article  CAS  PubMed  Google Scholar 

  26. Younes A, Ayoub J-P, Hagemeister FB et al. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule J Clin Oncol 1996 14: 543 548

    Article  CAS  PubMed  Google Scholar 

  27. Press OW, LeBlanc M, O'Rourke TJ et al. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology group Trial 9246 J Clin Oncol 1998 16: 574 578

    Article  CAS  PubMed  Google Scholar 

  28. Klimo P, Connors JM . MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma Ann Intern Med 1985 102: 596 602

    Article  CAS  PubMed  Google Scholar 

  29. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New Engl J Med 1995 333: 1540 1545

    Article  CAS  PubMed  Google Scholar 

  30. Rodriguez-Monge EJ, Cabanillas F . Long-term follow-up of platinum-based lymphoma salvage regimens. The MD Anderson Cancer Centre experience Hematol Oncol Clin N Amer 1997 11: 937 947

    Article  CAS  Google Scholar 

  31. Blay J-Y, Gomez F, Sebban C et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial Blood 1998 92: 3562 3568

    CAS  PubMed  Google Scholar 

  32. Freedman AS, Takvorian T, Anderson KC et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse J Clin Oncol 1990 8: 784 791

    Article  CAS  PubMed  Google Scholar 

  33. Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma J Clin Oncol 1995 13: 588 595

    Article  CAS  PubMed  Google Scholar 

  34. Guglielmi C, Gomez F, Philip T et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial J Clin Oncol 1998 16: 3264 3269

    Article  CAS  PubMed  Google Scholar 

  35. Phillips GL, Fay JW, Herzig RH et al. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation Blood 1990 75: 831 838

    CAS  PubMed  Google Scholar 

  36. Vose JM, Peterson C, Bierman PJ et al. Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas Blood 1990 76: 424 431

    CAS  PubMed  Google Scholar 

  37. Petersen FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle J Clin Oncol 1990 8: 638 647

    Article  CAS  PubMed  Google Scholar 

  38. Goldstone AH, Singer CRJ, Gribben JG et al. Experience of autologous bone marrow transplantation in the first 100 lymphomas Bone Marrow Transplant 1988 3: 33 36

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Toronto Autologous Blood and Marrow Transplant Program, Princess Margaret Hospital, University Health Network, Toronto, Canada

    CI Chen, D Roitman, R Tsang, AK Stewart, A Keating & M Crump

Authors
  1. CI Chen
    View author publications

    Search author on:PubMed Google Scholar

  2. D Roitman
    View author publications

    Search author on:PubMed Google Scholar

  3. R Tsang
    View author publications

    Search author on:PubMed Google Scholar

  4. AK Stewart
    View author publications

    Search author on:PubMed Google Scholar

  5. A Keating
    View author publications

    Search author on:PubMed Google Scholar

  6. M Crump
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, C., Roitman, D., Tsang, R. et al. ‘Relative’ chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 30, 885–891 (2002). https://doi.org/10.1038/sj.bmt.1703772

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703772

Keywords

This article is cited by

Search

Advanced search

Quick links